Malin Wennström, Henrietta M Nielsen, Funda Orhan, Elisabet Londos, Lennart Minthon, Sophie Erhardt
{"title":"Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.","authors":"Malin Wennström, Henrietta M Nielsen, Funda Orhan, Elisabet Londos, Lennart Minthon, Sophie Erhardt","doi":"10.4137/IJTR.S13958","DOIUrl":"https://doi.org/10.4137/IJTR.S13958","url":null,"abstract":"<p><p>Kynurenic acid (KYNA) is implicated in cognitive functions. Altered concentrations of the compound are found in serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD). Further studies to determine whether KYNA serves as a biomarker for cognitive decline and dementia progression are required. In this study, we measured CSF KYNA levels in AD patients (n = 19), patients with dementia with Lewy bodies (DLB) (n = 18), and healthy age-matched controls (Ctrls)) (n = 20) to further explore possible correlations between KYNA levels, cognitive decline, and well-established AD and inflammatory markers. Neither DLB patients nor AD patients showed significantly altered CSF KYNA levels compared to Ctrls. However, female AD patients displayed significantly higher KYNA levels compared to male AD patients, a gender difference not seen in the Ctrl or DLB group. Levels of KYNA significantly correlated with the AD-biomarker P-tau and the inflammation marker soluble intercellular adhesion molecule-1 (sICAM-1) in the AD patient group. No associations between KYNA and cognitive functions were found. Our study shows that, although KYNA was not associated with cognitive decline in AD or DLB patients, it may be implicated in AD-related hyperphosphorylation of tau and inflammation. Further studies on larger patient cohorts are required to understand the potential role of KYNA in AD and DLB. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"7 ","pages":"1-7"},"PeriodicalIF":4.4,"publicationDate":"2014-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/IJTR.S13958","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32364750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immunohistochemical studies of the kynurenine pathway in morphea.","authors":"Rowland Noakes, Nick Mellick","doi":"10.4137/IJTR.S13371","DOIUrl":"https://doi.org/10.4137/IJTR.S13371","url":null,"abstract":"<p><p>Cutaneous sclerosis, resembling that seen in subcutaneous morphea, is a feature of eosinophilic fasciitis and eosinophilia-myalgia syndrome, two conditions in which the kynurenine pathway is known to be activated. To investigate the possibility of activation of the kynurenine pathway in morphea, skin biopsies were taken from involved and non-involved sites in a series of three patients with morphea. Immunohistochemical stains for quinolinic acid and indoleamine 2,3-dioxygenase (IDO) were performed. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"97-102"},"PeriodicalIF":4.4,"publicationDate":"2013-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/IJTR.S13371","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31997534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ann Atlas, Elisabeth Franzen-Röhl, Johan Söderlund, Erik G Jönsson, Martin Samuelsson, Lilly Schwieler, Birgit Sköldenberg, Göran Engberg
{"title":"Sustained elevation of kynurenic Acid in the cerebrospinal fluid of patients with herpes simplex virus type 1 encephalitis.","authors":"Ann Atlas, Elisabeth Franzen-Röhl, Johan Söderlund, Erik G Jönsson, Martin Samuelsson, Lilly Schwieler, Birgit Sköldenberg, Göran Engberg","doi":"10.4137/IJTR.S13256","DOIUrl":"https://doi.org/10.4137/IJTR.S13256","url":null,"abstract":"<p><p>Herpes simplex virus (HSV) type 1 encephalitis (HSE) is a viral infectious disease with commonly occurring neurodegeneration and neurological/cognitive long-term sequelae. Kynurenic acid (KYNA) is a neuroactive tryptophan metabolite, which is elevated in the cerebrospinal fluid (CSF) during viral infection as a result of immune activation. The aim of the study was to investigate the role of endogenous brain KYNA for the long-term outcome of the disease. CSF KYNA concentration was analyzed in 25 HSE patients along the course of the disease and compared with that of 25 age-matched healthy volunteers. Within 3 weeks of admission CSF KYNA of HSE patients was markedly elevated (median 33.6 nM) compared to healthy volunteers (median 1.45 nM). Following a decline observed after 1-2 months, levels of CSF KYNA were elevated more than 1 year after admission (median 3.4 nM range: 1-9 years). A negative correlation was found between initial CSF KYNA concentrations and severity of the long-term sequelae. This study show a marked elevation in CSF KYNA from patients with HSE, most pronounced during the acute phase of the disease and slowly declining along the recovery. We propose that brain KYNA might potentially protect against neurodegeneration while causing a long-lasting loss in cognitive function associated with the disease. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"89-96"},"PeriodicalIF":4.4,"publicationDate":"2013-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/IJTR.S13256","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31943749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Big brains, meat, tuberculosis, and the nicotinamide switches: co-evolutionary relationships with modern repercussions?","authors":"Adrian C Williams, Robin I M Dunbar","doi":"10.4137/IJTR.S12838","DOIUrl":"https://doi.org/10.4137/IJTR.S12838","url":null,"abstract":"<p><p>Meat-eating was a game changer for human evolution. We suggest that the limiting factors for expanding brains earlier were scarcities of nicotinamide and tryptophan. In humans and some other omnivores, lack of meat causes these deficiencies. Nicotinamide adenine dinucleotide (NADH) is necessary to synthesize adenosine triphosphate (ATP) via either glycolysis or via the mitochondrial respiratory chain. NAD consumption is also necessary for developmental and repair circuits. Inadequate supplies result in \"de-evolutionary\" brain atrophy, as seen with pellagra. If trophic nicotinamide/tryptophan was a \"prime mover\" in building bigger brains, back-up mechanisms should have evolved. One strategy may be to recruit extra gut symbionts that produce NADH precursors or export nicotinamide (though this may cause diarrhea). We propose a novel supplier TB that co-evolved early, which did not originally and does not now inevitably cause disease. TB has highly paradoxical immunology for a pathogen, and secretes and is inhibited by nicotinamide and its analogue, isoniazid. Sharp declines in TB and diarrhea correlated with increased meat intake in the past, suggesting that dietary vitamin B3 and tryptophan deficiencies (also associated with poor cognition and decreased lifespans) are still common where meat is unaffordable. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"73-88"},"PeriodicalIF":4.4,"publicationDate":"2013-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/IJTR.S12838","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31880134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effects of tranilast on the urinary excretion of kynurenic and quinolinic Acid under conditions of L tryptophan loading.","authors":"Rowland R Noakes","doi":"10.4137/IJTR.S12797","DOIUrl":"https://doi.org/10.4137/IJTR.S12797","url":null,"abstract":"<p><p>The pathogenesis of morphea and other cutaneous sclerosing disorders remain poorly understood. Although they are considered to be autoimmune disorders, abnormal tryptophan metabolism may be involved. Current therapy is directed to supressing the autoimmune response. Demonstration of a therapeutic response to manipulation of the kynurenine pathway would both support a role for abnormal tryptophan metabolism and offer additional targets for therapy. Tranilast is a 3-hydroxyanthranilic acid derivative known to target the kynurenine pathway. The aim of this study was to see if tranilast lowered the urinary excretion of the kynurenine metabolites kynurenic and quinolinic acid under condition of L tryptophan loading in a volunteer. Mean baseline value for kynurenic acid and quinolinic acid were 1.1 and 2.1 mmol/mol creatinine, respectively. This rose to 5.6 and 3.8 mmol/mol creatinine respectively under conditions of L tryptophan loading 2 grams daily. Adding 1 g of tranilast daily lowered the values to 2.0 and 2.9 mmol/mol creatinine, respectively. These data suggest that tranilast acts as a competitive inhibitor of either indoleamine 2, 3-dioxygenase (IDO), tryptophan 2, 3-di-oxygenase (TDO) or both. As it involved only 1 subject, the results may not be representative of the larger population and must be considered preliminary. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"67-71"},"PeriodicalIF":4.4,"publicationDate":"2013-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/IJTR.S12797","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31780433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The kynurenine pathway in stem cell biology.","authors":"Simon P Jones, Gilles J Guillemin, Bruce J Brew","doi":"10.4137/IJTR.S12626","DOIUrl":"10.4137/IJTR.S12626","url":null,"abstract":"<p><p>The kynurenine pathway (KP) is the main catabolic pathway of the essential amino acid tryptophan. The KP has been identified to play a critical role in regulating immune responses in a variety of experimental settings. It is also known to be involved in several neuroinflammatory diseases including Huntington's disease, amyotrophic lateral sclerosis, and Alzheimer's disease. This review considers the current understanding of the role of the KP in stem cell biology. Both of these fundamental areas of cell biology have independently been the focus of a burgeoning research interest in recent years. A systematic review of how the two interact has not yet been conducted. Several inflammatory and infectious diseases in which the KP has been implicated include those for which stem cell therapies are being actively explored at a clinical level. Therefore, it is highly relevant to consider the evidence showing that the KP influences stem cell biology and impacts the functional behavior of progenitor cells. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"57-66"},"PeriodicalIF":4.4,"publicationDate":"2013-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31780434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michal P Turski, Monika Turska, Piotr Paluszkiewicz, Jolanta Parada-Turska, Gregory F Oxenkrug
{"title":"Kynurenic Acid in the digestive system-new facts, new challenges.","authors":"Michal P Turski, Monika Turska, Piotr Paluszkiewicz, Jolanta Parada-Turska, Gregory F Oxenkrug","doi":"10.4137/IJTR.S12536","DOIUrl":"10.4137/IJTR.S12536","url":null,"abstract":"<p><p>This review provides information on the most recent findings concerning presence, origin, and role of kynurenic acid (KYNA), a tryptophan metabolite, in the digestive system. KYNA is an antagonist of both the ionotropic glutamate receptors and the alpha7 nicotinic acetylcholine receptor, as well as an agonist of G-protein coupled GPR35 receptor. Since the GPR35 receptor is mainly present in the gastrointestinal tract, researchers have concentrated on the digestive system in recent years. They have found that KYNA content increases gradually and significantly along the gastrointestinal tract. Interestingly, the concentration of KYNA in the lumen is much higher than in the wall of intestine. It has been documented that KYNA may have a positive influence on the number of pathologies in the gastrointestinal tract, in particular ulcers, colon obstruction, or colitis. Future studies might determine whether it is advisable to supplement KYNA to a human organism. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"47-55"},"PeriodicalIF":2.7,"publicationDate":"2013-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31744846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hollie E Flick, Judith M Lalonde, William P Malachowski, Alexander J Muller
{"title":"The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1.","authors":"Hollie E Flick, Judith M Lalonde, William P Malachowski, Alexander J Muller","doi":"10.4137/IJTR.S12094","DOIUrl":"10.4137/IJTR.S12094","url":null,"abstract":"<p><p>β-lapachone is a naturally occurring 1,2-naphthoquinone-based compound that has been advanced into clinical trials based on its tumor-selective cytotoxic properties. Previously, we focused on the related 1,4-naphthoquinone pharmacophore as a basic core structure for developing a series of potent indoleamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitors. In this study, we identified IDO1 inhibitory activity as a previously unrecognized attribute of the clinical candidate β-lapachone. Enzyme kinetics-based analysis of β-lapachone indicated an uncompetitive mode of inhibition, while computational modeling predicted binding within the IDO1 active site consistent with other naphthoquinone derivatives. Inhibition of IDO1 has previously been shown to breach the pathogenic tolerization that constrains the immune system from being able to mount an effective anti-tumor response. Thus, the finding that β-lapachone has IDO1 inhibitory activity adds a new dimension to its potential utility as an anti-cancer agent distinct from its cytotoxic properties, and suggests that a synergistic benefit can be achieved from its combined cytotoxic and immunologic effects. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"35-45"},"PeriodicalIF":4.4,"publicationDate":"2013-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31723111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ai Tsuji, Chifumi Nakata, Mitsue Sano, Tsutomu Fukuwatari, Katsumi Shibata
{"title":"L-tryptophan metabolism in pregnant mice fed a high L-tryptophan diet and the effect on maternal, placental, and fetal growth.","authors":"Ai Tsuji, Chifumi Nakata, Mitsue Sano, Tsutomu Fukuwatari, Katsumi Shibata","doi":"10.4137/IJTR.S12715","DOIUrl":"https://doi.org/10.4137/IJTR.S12715","url":null,"abstract":"<p><p>Excess L-tryptophan (L-Trp) in the diet decreases fetal body weight. However, the relationship between L-Trp concentration and its effects on maternal, placental, and fetal growth are not well-understood. We investigated the effects of excess L-Trp intake on maternal, placental, and fetal growth. Female mice were fed a 20% casein diet (control diet) or control diet plus 2% or 5% L-Trp during gestation. Pup weights did not differ between the control (L-Trp intake: 0.04 g/kg body weight (BW)/day) and 2% L-Trp groups (L-Trp intake: 3.3 g/kg BW/day), but were significantly lower in the 5% L-Trp group (L-Trp intake: 7.0 g/kg BW/day) than in the control and 2% L-Trp groups. These results show that less than 3.3 g/kg BW/day L-Trp intake in pregnant mice during gestation does not affect fetal growth or L-Trp homeostasis in the placenta or fetus. </p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"21-33"},"PeriodicalIF":4.4,"publicationDate":"2013-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/IJTR.S12715","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31711484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chai K Lim, Margaret M C Yap, Stephen J Kent, Gabriel Gras, Boubekeur Samah, Jane C Batten, Robert De Rose, Benjamin Heng, Bruce J Brew, Gilles J Guillemin
{"title":"Characterization of the kynurenine pathway and quinolinic Acid production in macaque macrophages.","authors":"Chai K Lim, Margaret M C Yap, Stephen J Kent, Gabriel Gras, Boubekeur Samah, Jane C Batten, Robert De Rose, Benjamin Heng, Bruce J Brew, Gilles J Guillemin","doi":"10.4137/IJTR.S11789","DOIUrl":"https://doi.org/10.4137/IJTR.S11789","url":null,"abstract":"<p><p>The kynurenine pathway (KP) and one of its end-products, the excitotoxin quinolinic acid (QUIN), are involved in the pathogenesis of several major neuroinflammatory brain diseases. A relevant animal model to study KP metabolism is now needed to assess whether intervention in this pathway may improve the outcome of such diseases. Humans and macaques share a very similar genetic makeup. In this study, we characterized the KP metabolism in macaque primary macrophages of three different species in comparison to human cells. We found that the KP profiles in simian macrophages were very similar to those in humans when challenged with inflammatory cytokines. Further, we found that macaque macrophages are capable of producing a pathophysiological concentration of QUIN. Our data validate the simian model as a relevant model to study the human cellular KP metabolism in the context of inflammation.</p>","PeriodicalId":46603,"journal":{"name":"International Journal of Tryptophan Research","volume":"6 ","pages":"7-19"},"PeriodicalIF":4.4,"publicationDate":"2013-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/IJTR.S11789","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31594608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}